Fortive Corp Q3 FY2025 earnings call

Management Statement and Operational Highlights

• Teams executing well with laser focus on profitable organic growth, driving core growth ~2%, adjusted EBITDA growth 10%, adjusted EPS growth 15%.
• Raised full-year adjusted EPS guidance to $2.63-$2.67 per share.
• Deployed $1 billion to share repurchases in Q3, retiring ~21 million shares.
• Strategy execution: Focus on innovation acceleration (product launches, innovation studios), commercial acceleration (focus on high-growth markets like solar, data centers, India), recurring customer value (increasing recurring revenues), and disciplined capital allocation (investing in organic growth, accretive M&A, share repurchases, and dividends).

Segment Performance

• Intelligent Operating Solutions (iOS): Reported revenue grew just over 2.5%, core revenue growth 2%. Driven by facility and asset lifecycle software, professional instrumentation, and gas detection. Adjusted gross margin declined ~90 basis points to 65.7% due to tariff costs, but adjusted EBITDA grew 7% to $242 million, margin 34.6%.
• Advanced Healthcare Solutions (AHS): Total revenue $328 million, grew ~2% reported, ~1% core. Software products performing well, healthcare equipment and consumables showed sequential improvement. Adjusted gross margin 58.4%, adjusted EBITDA grew ~7%, margin 28%.

Guidance

• Raised full-year adjusted EPS guidance to $2.63-$2.67 per share, reflecting Q3 overperformance, buybacks, and unchanged Q4 view.
• Expect core growth to moderate in Q4, with AHS core growth broadly in line with Q3 and iOS having very modest core growth.
• Full-year adjusted effective tax rate expected in mid-teens, Q4 tax rate in single digits due to discrete items.
• Sequential increase in net interest expense in Q4 due to cash and debt levels at quarter end.

Risks

• Market conditions and macroeconomic factors (e.g., weakening in Europe, mixed rest of world).
• Tariff-related costs impacting margins.
• Uncertainty from healthcare reimbursement and funding policy changes affecting AHS segment.

Q: Nigel Coe asked about margin performance and Q4 expectations, specifically tariff offsets and government shutdown impact.

A: Mark D. Okerstrom discussed one-timers in Q3 affecting margins and Olumide Soroye noted limited direct federal government exposure.

Q: Deane Dray inquired about capital allocation, buybacks, and M&A priorities.

A: Olumide Soroye explained share repurchases based on attractive valuations and M&A focus on smaller bolt-on acquisitions.

Q: Scott Davis asked about Landauer's outlook in AHS.

A: Olumide Soroye mentioned Landauer's strong recurring growth and innovation efforts.

Q: Julian Mitchell asked about AHS demand trends and tax rate outlook.

A: Olumide Soroye discussed sequential improvements in AHS capital and consumables, and Mark D. Okerstrom spoke about mid-teens tax rate outlook.

Q: Steve Tusa asked about software business performance and Fluke growth.

A: Olumide Soroye highlighted Fluke's growth and software's role in driving recurring revenue.

Q: Andy Kaplowitz asked about simplification impact on future performance.

A: Olumide Soroye stated simplification would continue to drive growth.

Q: Jeff Sprague inquired about margin trajectory and Q4 OpEx.

A: Mark D. Okerstrom explained one-timers in Q3 and expected OpEx increase in Q4.

Q: Joe O'Dea asked about resourcing growth oxygen for brands and organic growth composition.

A: Olumide Soroye discussed strategic planning and ideas driving growth.

Q: Chris Snyder asked about Q4 organic growth moderation and AHS policy confidence.

A: Mark D. Okerstrom and Olumide Soroye addressed comps and secular trends supporting AHS.

Q: Jamie Cook asked about upside potential and adjusted operating profit components.

A: Olumide Soroye and Mark D. Okerstrom discussed financial framework and separation-related costs.

Q: Joseph Giordano asked about recurring revenue percentage and levers.

A: Olumide Soroye discussed shifting to more recurring offerings, especially at Fluke.

Q: Andrew Buscaglia asked about margin dependence on volume and stranded costs.

A: Mark D. Okerstrom addressed volume impact on margins and progress on stranded costs.